Literature DB >> 10905580

Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis.

K Hiramatsu1, K Harada, K Tsuneyama, M Sasaki, S Fujita, T Hashimoto, S Kaneko, K Kobayashi, Y Nakanuma.   

Abstract

BACKGROUND/AIMS: The etiopathogenesis of bile duct lesion in primary biliary cirrhosis is unknown, though the participation of bacteria and/or their components and products is suspected. In this study, we tried to detect and identify bacteria in the bile of patients with primary biliary cirrhosis by polymerase chain reaction using universal bacterial primers of the 16S ribosomal RNA gene.
METHODS: Gallbladder bile samples from 15 patients with primary biliary cirrhosis, 5 with primary sclerosing cholangitis, 5 with hepatitis C virus-related liver cirrhosis, 11 with cholecystolithiasis, and from 12 normal adult gallbladders were used. In addition to the culture study, partial bacterial 16S ribosomal RNA gene was amplified by polymerase chain reaction (PCR) taking advantage of universal primers that can amplify the gene of almost all bacterial species, and the amplicons were cloned and sequenced. Sequence homology with specific bacterial species was analyzed by database research. Bacterial contamination at every step of the bile sampling, DNA extraction and PCR study was avoided. Furthermore, to confirm whether bacterial DNA is detectable in liver explants, the same analysis was performed using 10 liver explants of patients with primary biliary cirrhosis.
RESULTS: In primary biliary cirrhosis, 75% (p<0.0001) of 100 clones were identified as so-called gram-positive cocci while these cocci were positive in only 5% in cholecystolithiasis (p<0.0001). In cholecystolithiasis gram-negative rods were predominant instead. One bacterial species detected in a normal adult was not related to those detected in primary biliary cirrhosis and cholecystolithiasis patients. No bacterial DNA was detected by PCR amplification in 10 liver explants of patients with primary biliary cirrhosis.
CONCLUSIONS: The present results raise several possible roles of gram-positive bacteria in bile in the etiopathogenesis of primary biliary cirrhosis. However, these results could also reflect an epiphenomenon due to decreased bile flow in the patients with primary biliary cirrhosis at an advanced stage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10905580     DOI: 10.1016/s0168-8278(00)80153-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  27 in total

1.  Involvement of commensal bacteria may lead to dysregulated inflammatory and autoimmune responses in a mouse model for chronic nonsuppurative destructive cholangitis.

Authors:  Ikuko Haruta; Ken Kikuchi; Minoru Nakamura; Katsuhiko Hirota; Hidehito Kato; Hiroshi Miyakawa; Noriyuki Shibata; Yoichiro Miyake; Etsuko Hashimoto; Keiko Shiratori; Junji Yagi
Journal:  J Clin Immunol       Date:  2012-06-03       Impact factor: 8.317

2.  Identification of beta-subunit of bacterial RNA-polymerase--a non-species-specific bacterial protein--as target of antibodies in primary biliary cirrhosis.

Authors:  Kai-Wolfgang Roesler; Wolfgang Schmider; Manfred Kist; Stephen Batsford; Emile Schiltz; Mathias Oelke; Anja Tuczek; Therese Dettenborn; Dirk Behringer; Wolfgang Kreisel
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

Review 3.  The immunobiology of cholangiocytes.

Authors:  Xian-Ming Chen; Steven P O'Hara; Nicholas F LaRusso
Journal:  Immunol Cell Biol       Date:  2008-05-27       Impact factor: 5.126

4.  Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.

Authors:  James H Tabibian; Steven P O'Hara; Christy E Trussoni; Pamela S Tietz; Patrick L Splinter; Taofic Mounajjed; Lee R Hagey; Nicholas F LaRusso
Journal:  Hepatology       Date:  2015-08-10       Impact factor: 17.425

Review 5.  Advances in cholangiocyte immunobiology.

Authors:  Gaurav Syal; Michel Fausther; Jonathan A Dranoff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-09-06       Impact factor: 4.052

6.  Primary sclerosing cholangitis: A review and update.

Authors:  James H Tabibian; Christopher L Bowlus
Journal:  Liver Res       Date:  2017-12

Review 7.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

8.  PPARγ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis.

Authors:  Yusuke Nozaki; Kenichi Harada; Takahiro Sanzen; Yasuni Nakanuma
Journal:  Med Mol Morphol       Date:  2013-02-09       Impact factor: 2.309

9.  Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.

Authors:  James H Tabibian; Andrea Gossard; Mounif El-Youssef; John E Eaton; Jan Petz; Roberta Jorgensen; Felicity B Enders; Anilga Tabibian; Keith D Lindor
Journal:  Am J Ther       Date:  2017 Jan/Feb       Impact factor: 2.688

Review 10.  The enteric microbiome in hepatobiliary health and disease.

Authors:  James H Tabibian; Cyril Varghese; Nicholas F LaRusso; Steven P O'Hara
Journal:  Liver Int       Date:  2015-12-12       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.